<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894541</url>
  </required_header>
  <id_info>
    <org_study_id>148FDI16004</org_study_id>
    <nct_id>NCT02894541</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 1-sequence, 3-treatment, 3-period Crossover Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of food on the
      pharmacokinetics/pharmacodynamics of CKD-519.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, single dose, 1-sequence, 3-treatment, 3-period crossover study to
      investigate the effects of food on the pharmacokinetics/pharmacodynamics of CKD-519 in
      healthy male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of CKD-519</measure>
    <time_frame>0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of CKD-519</measure>
    <time_frame>0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of CKD-519</measure>
    <time_frame>0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of CKD-519</measure>
    <time_frame>0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of CKD-519</measure>
    <time_frame>0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of CKD-519</measure>
    <time_frame>0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vd/F of CKD-519</measure>
    <time_frame>0(predose)~168</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibition of CETP(Cholesteryl ester transfer protein) Activity</measure>
    <time_frame>0(predose)~168</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>CKD-519 tablet 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 tablet(formulation Ⅱ) 100mg(100mg X 1Tab) Period 1: CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-519 tablet 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 tablet(formulation Ⅱ) 200mg(100mg X 2Tabs) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-519 soft capsule 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 soft capsule(formulation Ⅲ) 100mg(100mg X 1Cap) Period 1:CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-519 soft capsule 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 soft capsule(formulation Ⅲ) 200mg(100mg X 2Caps) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 100mg</intervention_name>
    <arm_group_label>CKD-519 tablet 100mg</arm_group_label>
    <other_name>CKD-519 tablet(formulation Ⅱ) 100mg(100mg X 1Tab)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 200mg</intervention_name>
    <arm_group_label>CKD-519 tablet 200mg</arm_group_label>
    <other_name>CKD-519 tablet(formulation Ⅱ) 200mg(100mg X 2Tabs)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 100mg</intervention_name>
    <arm_group_label>CKD-519 soft capsule 100mg</arm_group_label>
    <other_name>CKD-519 soft capsule(formulation Ⅲ) 100mg(100mg X 1Cap)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 200mg</intervention_name>
    <arm_group_label>CKD-519 soft capsule 200mg</arm_group_label>
    <other_name>CKD-519 soft capsule(formulation Ⅲ) 200mg(100mg X 2Caps)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 20 aged and 45 aged in healthy adult male

          -  Body weight more than 50, Body Mass Index between 18 and 29kg/m²

          -  Necessarily he agrees that use double contraceptions and do not sperm donation until
             two months during clinical trials and after the final dosage of investigational
             products

          -  Those who fully understand about this clinical trials after enough hearing, and then
             decided to join the clinical trials by themselves and to comply with the precautions
             written consent

        Exclusion Criteria:

          -  Clinically significant disease with cardiovascular, respiratory, hepatobiliary,
             nephrological, hematological, gastrointestinal, endocrine, immune, integumentary,
             neurologic, psychiatric system

          -  Have a acute disease within 28 days before the beginning of study treatment

          -  Have a disease history that can effect drug absorption, distribution, metabolism,
             excretion

          -  Have a clinically significant chronic disease

          -  Systolic blood pressure&lt;100mmHg or&gt;140mmHg, diastolic blood pressure&lt;60mmHg or&gt;90mmHg

          -  Defined by the following 12-lead ECG, QTc&gt;450msec

          -  Positive for serology test (HBsAg, anti-HCV Ab, anti-HIV Ab, VDRL(Venereal Disease
             Research Laboratories))

          -  Subject treated ethical drug within 14 days before the beginning of study treatment

          -  Subject treated over-the-counter or herbal medicine within 7 days before the beginning
             of study treatment

          -  Have a clinically significant allergic disease (except for mild allergic rhinitis,
             allergic dermatitis with no drugs)

          -  Cannot take standard Meal

          -  Whole blood donation within 60 days prior to the first dosing or component blood
             donation within 20 days prior to the first dosing

          -  Blood transfusion within 30 days

          -  Taking drugs have received any other investigational drug within 90 days prior to the
             first dosing

          -  Subject treated metabolizing enzyme inducers or inhibitors including barbiturates
             within 30 days

          -  Continuously taking caffeine(caffeine&gt;5 cups/day), drinking
             alcohol(alcohol&gt;210g/week), smoking excessive cigarettes(cigarette&gt;10cigarettes/day)

          -  Impossible on who participants in clinical trial by investigator's decision including
             laboratory test result or another reasons(for example, noncompliance, a disobliging
             manner)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Young Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea university medical center</name>
      <address>
        <city>Seoul</city>
        <state>Sungbuk-gu</state>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>CKD-519</keyword>
  <keyword>CETP inhibitor</keyword>
  <keyword>Food Drug Interaction</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

